Roussel Uclaf

Last updated
Roussel-Uclaf S.A.
Type Public (Société anonyme)
Industry Pharmaceutical
Founded Paris, France (1911 (1911))
Institut de Sérothérapie Hémopoïétique
ISH (1920)
Usines Chimiques des Laboratoires Français
UCLAF (1928)
Société Française de la Pénicilline
SOFRAPEN (1947)
(Roussel-Uclaf, S.A. incorporated 1961)
FounderGaston Roussel
DefunctSeptember 30, 1997 (September 30, 1997) [1]
FateAcquired
Successor Hoechst AG (Hoechst Marion Roussel)
Headquarters Paris, France (1911–1995)
Romainville, France (1995–1997) [2]
Area served
Worldwide
Key people
Gaston Roussel (CEO, 1911–1947)
Jean-Claude Roussel (CEO, 1961–1972)
Jacques Machizaud (CEO, 1974–1981)
Édouard Sakiz (CEO, 1981–1993)
Ernst-Günter Afting (CEO, 1994–1995)
Jean-Pierre Godard (CEO, 1995–1997)
ProductsHemostyl (erythropoietin, horse serum)
Rubiazol (carboxysulfamidochrysoidine)
Rythmodan (disopyramide)
Decis (deltamethrin)
Surgam (tiaprofenic acid)
Claforan (cefotaxime sodium)
Mifegyne (mifepristone, RU-486)
Anandron (nilutamide)
RevenueIncrease2.svg US$ 3.01 billion (1996) [3]
Increase2.svg US$ 340 million(1996) [3]
Number of employees
15,673 worldwide (1992) [4]
  8,409 in France (1992) [4]
  6,533 in France (1996) [5]

Roussel Uclaf S.A. was a French pharmaceutical company and one of several predecessor companies of today's Sanofi.

Contents

It was the second largest French pharmaceutical company [6] before it was acquired by Hoechst AG of Frankfurt, Germany in 1997, with pharmaceutical operations combined into the Hoechst Marion Roussel (HMR) division in the United States. Roussel Uclaf's agrochemical operations had been transferred to Hoechst Schering AgrEvo GmbH in 1994.

HMR subsequently merged in 1999 with Rhône-Poulenc to form Aventis, which then merged in 2004 with Sanofi-Synthélabo to form Sanofi-Aventis, which was since renamed Sanofi. Hoechst Schering AgrEvo merged in 1999 with Rhône-Poulenc's agrochemical division to form Aventis CropScience, which was acquired by Bayer AG in 2002 and combined with Bayer's agrochemical division to form Bayer CropScience.

RU-486

In April 1980, as part of a formal research project at Roussel-Uclaf for the development of glucocorticoid receptor antagonists, chemist Georges Teutsch synthesized mifepristone (RU-38486, the 38,486th compound synthesized by Roussel-Uclaf from 1949 to 1980; shortened to RU-486); which was discovered to also be a progesterone receptor antagonist. [7] [8] In October 1981, endocrinologist Étienne-Émile Baulieu, a consultant to Roussel-Uclaf, arranged tests of its use for medical abortion in eleven women in Switzerland by gynecologist Walter Herrmann at the University of Geneva's Cantonal Hospital, with successful results announced on April 19, 1982. [7] [9] On October 9, 1987, following worldwide clinical trials in 20,000 women of mifepristone with a prostaglandin analogue (initially sulprostone or gemeprost, later misoprostol) for medical abortion, Roussel-Uclaf sought approval in France for their use for medical abortion, with approval announced on September 23, 1988. [7] [10]

Abortion Products

On October 21, 1988, in response to antiabortion protests and concerns of majority (54.5%) owner Hoechst AG of Germany, Roussel-Uclaf's executives and board of directors voted 16 to 4 to stop distribution of mifepristone, which they announced on October 26, 1988. [7] [11] Two days later, the French government ordered Roussel-Uclaf to distribute mifepristone in the interests of public health. [7] [12] French Health Minister Claude Évin explained that: "I could not permit the abortion debate to deprive women of a product that represents medical progress. From the moment Government approval for the drug was granted, RU-486 became the moral property of women, not just the property of a drug company." [7] Following use by 34,000 women in France from April 1988 to February 1990 of mifepristone distributed free of charge, Roussel-Uclaf began selling Mifegyne (mifepristone) to hospitals in France in February 1990 at a price (negotiated with the French government) of $48 per 600 mg dose. [7]

Mifegyne was subsequently approved in Great Britain on July 1, 1991, [13] and in Sweden in September 1992, [14] but until his retirement in late April 1994, Hoechst AG chairman Wolfgang Hilger, a devout Roman Catholic, blocked any further expansion in availability. [7] [15] On May 16, 1994, Roussel-Uclaf announced that it was donating without remuneration all rights for medical uses of mifepristone in the U.S. to the Population Council, [16] which subsequently licensed mifepristone to Danco Laboratories, a new single-product company immune to antiabortion boycotts, which won FDA approval as Mifeprex on September 28, 2000. [17]

On April 8, 1997, after buying the remaining 43.5% of Roussel-Uclaf stock in early 1997, [18] Hoechst AG ($30 billion annual revenue) announced the end of its manufacture and sale of Mifegyne ($3.44 million annual revenue) and the transfer of all rights for medical uses of mifepristone outside of the U.S. to Exelgyn S.A., a new single-product company immune to antiabortion boycotts, whose CEO was former Roussel-Uclaf CEO Édouard Sakiz. [19] In 1999, Exelgyn won approval of Mifegyne in 11 additional countries, and in 28 more countries over the following decade. [20]

Related Research Articles

<span class="mw-page-title-main">Mifepristone</span> Medication

Mifepristone, also known as RU-486, is a medication typically used in combination with misoprostol to bring about a medical abortion during pregnancy and manage early miscarriage. This combination is 97% effective during the first 63 days of pregnancy. It is also effective in the second trimester of pregnancy. It is taken by mouth.

<span class="mw-page-title-main">Hoechst AG</span> German chemicals company

Hoechst AG was a German chemicals then life-sciences company that became Aventis Deutschland after its merger with France's Rhône-Poulenc S.A. in 1999. With the new company's 2004 merger with Sanofi-Synthélabo, it became a subsidiary of the resulting Sanofi-Aventis pharmaceuticals group.

<span class="mw-page-title-main">Telithromycin</span> Chemical compound

Telithromycin is the first ketolide antibiotic to enter clinical use and is sold under the brand name of Ketek. It is used to treat community acquired pneumonia of mild to moderate severity. After significant safety concerns, the US Food and Drug Administration sharply curtailed the approved uses of the drug in early 2007.

<span class="mw-page-title-main">King Pharmaceuticals</span> American pharmaceutical company

King Pharmaceuticals, is a pharmaceutical company, a wholly owned subsidiary of Pfizer based in Bristol, Tennessee. Before being acquired by Pfizer, it was the world's 39th largest pharmaceutical company. On October 12, 2010, King was acquired by Pfizer for $14.25 per share. King produced a wide range of pharmaceuticals, including Altace for heart attack prevention, Levoxyl for hypothyroidism, Sonata, a sleeping aid, and Skelaxin, a muscle relaxant. King Pharmaceuticals operated manufacturing facilities in Bristol, Tennessee; Rochester, Michigan; St. Louis, Missouri; St. Petersburg, Florida; and Middleton, Wisconsin. They employed approximately 2,700 people including a sales force of over 1,000 individuals.

Rhône-Poulenc was a French chemical and pharmaceutical company founded in 1928. In 1999 it merged with Hoechst AG to form Aventis. As of 2015, the pharmaceutical operations of Rhône-Poulenc are part of Sanofi and the chemicals divisions are part of Solvay group and Bayer Crop Science.

John M. Gregory is a former CEO of King Pharmaceuticals, Inc. and resides in Bristol, Tennessee. In addition to founding King Pharmaceuticals in 1993, Gregory has founded several other notable business ventures including SJ Strategic Investments and Leitner Pharmaceuticals. Gregory has also made major investment outside of the pharmaceutical industry, such as his investments within the privately held United Coal Company located in southwest Virginia and Adams Golf with U.S. corporate offices in Texas. Most recently, Gregory, along with other family members, began Gregory Pharmaceutical Holdings Inc. which include pharmaceutical contract manufacturing company, UPM Pharmaceuticals, and NFI Consumer Products which includes the Blue-Emu brand of products.

<span class="mw-page-title-main">Claude Évin</span> French politician and lawyer

Claude Évin is a French politician and lawyer.

<span class="mw-page-title-main">Prenylamine</span> Chemical compound

Prenylamine (Segontin) is a calcium channel blocker of the amphetamine chemical class that was used as a vasodilator in the treatment of angina pectoris.

Marion Merrell Dow and its predecessor Marion Laboratories was a U.S. pharmaceutical company based in Kansas City, Missouri, from 1950 until 1996.

<span class="mw-page-title-main">Cassella</span>

Cassella AG, formerly Leopold Cassella & Co. and Cassella Farbwerke Mainkur AG, commonly known as Cassella, was a German chemical and pharmaceutical company with headquarters in Frankfurt am Main. Founded in 1798, in the Frankfurt Jewish Alley by Leopold Cassella, Cassella operated as an independent company until 1995, and was one of many predecessor companies of today's Sanofi. Its main products were dyes, drugs, cosmetics and various other chemical products. From 1949, Cassella focused increasingly on pharmaceuticals and cosmetics rather than its former primary focus, dyes. Much of its history is closely associated with the Gans family, a prominent family of industrialists and philanthropists and former owners of Cassella.

Hoechst Schering AgrEvo GmbH was a Düsseldorf-based limited liability company owned by Hoechst AG and Schering AG that only existed as an independent company for five years, from 1994 to 1999.

<span class="mw-page-title-main">Besipirdine</span> Chemical compound

Besipirdine, an indole-substituted analog of 4-aminopyridine, is a nootropic drug developed for the treatment of Alzheimer's disease (AD).

<span class="mw-page-title-main">Pascal Soriot</span> French businessman

Sir Pascal Claude Roland Soriot is a French-born Australian businessman and chief executive officer (CEO) of the British-Swedish multinational pharmaceutical and biotechnology company AstraZeneca.

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD, and by chief medical officer Robert S. Fishman, MD.

A medical abortion, also known as medication abortion, occurs when drugs (medication) are used to bring about an abortion. Medical abortions are an alternative to surgical abortions such as vacuum aspiration or dilation and curettage. Medical abortions are more common than surgical abortions in most places, including Europe, India, China, and the United States.

<span class="mw-page-title-main">RU-58841</span> Chemical compound

RU-58841, also known as PSK-3841 or HMR-3841, is a nonsteroidal antiandrogen (NSAA) which was initially developed in the 1980s by Roussel Uclaf, the French pharmaceutical company from which it received its name. It was formerly under investigation by ProStrakan for potential use as a topical treatment for androgen-dependent conditions including acne, pattern hair loss, and excessive hair growth. The compound is similar in structure to the NSAA RU-58642 but contains a different side-chain. These compounds are similar in chemical structure to nilutamide, which is related to flutamide, bicalutamide, and enzalutamide, all of which are NSAAs similarly. RU-58841 can be synthesized either by building the hydantoin moiety or by aryl coupling to 5,5-dimethylhydantoin.

<span class="mw-page-title-main">Toripristone</span> Chemical compound

Toripristone (INN) is a synthetic, steroidal antiglucocorticoid as well as antiprogestogen which was never marketed. It is reported as a potent and highly selective antagonist of the glucocorticoid receptor (GR), though it also acts as an antagonist of the progesterone receptor (PR). The pharmacological profile of toripristone is said to be very similar to that of mifepristone, except that toripristone does not bind to orosomucoid. The drug has been used to study the hypothalamic-pituitary-adrenal axis and has been used as a radiotracer for the GR. Its INN was given in 1990.

References

  1. ↑ Flallo, Laurent (October 2, 1997). "Hoechst Marion Roussel France touché par une des taxes Aubry". Les Échos. p. 8. Hoechst Marion Roussel France - ex-Roussel Uclaf, which juridically disappeared yesterday...
  2. ↑ Aizicovici, Francine (March 7, 1994). "Le désarroi des salariés". Le Monde. headquarters moved to Romainville in April 1995 after 40 years at 35 Boulevard des Invalides, Paris.
  3. 1 2 "Roussel UCLAF: profits en hausse de 11%". l'Humanité. February 18, 1997.
    "Hoechst AG: Roussel Uclaf unit posts net profit increase of 90%". The Wall Street Journal. February 18, 1997. p. A6. 1996: $3.01 billion sales, $339.5 million net profit
  4. 1 2 "Country focus: French chemicals: an industry review". Chemical Week. May 5, 1993. p. S14.
    Roussel Uclaf
    Sales 1992: F14.8 billion (3.5%). Profit before tax 1992: F1.439 billion (43%). Investment in assets 1992: F930 million (11.8%). Acquisitions in 1992: F452 million. Employees: 15,673; 8,409 of whom are in France. Principal products: Pharmaceuticals (57% of sales), agroveterinary products (23%), bulk pharmaceuticals (13%) and OTC and cosmetics (4%). Roussel Uclaf is owned 65% by Hoechst and 35% by Rhone-Poulenc, which might soon sell its stake to Hoechst. Headquarters: Paris.
  5. ↑ Lemaître, Frédéric (December 3, 1996). "Roussel-Uclaf adopte les 35 heures de travail hebdomadaires sans perte de salaire". Le Monde. 6,533 employees in France
  6. ↑ "Roussel Uclaf disappears, giving way to Hoechst Marion Russell". Chemical Business NewsBase. Cambridge: Royal Society of Chemistry. October 14, 1997. 2nd largest pharmaceutical company (after Rhône-Poulenc and ahead of Sanofi)
  7. 1 2 3 4 5 6 7 8 Baulieu, Étienne-Émile; Rosenblum, Mort (1991). The "abortion pill": RU-486, a woman's choice . New York: Simon & Schuster. ISBN   0-671-73816-X.
    Lader, Lawrence (1991). RU 486: the pill that could end the abortion wars and why American women don't have it . Reading: Addison-Wesley. ISBN   0-201-57069-6.
    Villaran, Gilda (1998). "RU 486". In Schlegelmilch, Bodo B. (ed.). Marketing ethics: an international perspective. London: Thomson Learning. pp. 155–190. ISBN   1-86152-191-X.
    Ulmann, André (2000). "The development of mifepristone: a pharmaceutical drama in three acts". J Am Med Womens Assoc. 55 (3 Suppl): 117–20. PMID   10846319.
  8. ↑ Teutsch, Georges (November 24, 1989). "RU 486 development". Science. 246 (4933): 985. doi:10.1126/science.2587990. PMID   2587990. S2CID   41144964.
    Cherfas, Jeremy (November 24, 1989). "Dispute surfaces over paternity of RU 486". Science. 246 (4933): 994. Bibcode:1989Sci...246..994C. doi:10.1126/science.2587988. PMID   2587988.
    Philibert, Daniel; Teutsch, Georges (February 9, 1990). "RU 486 development". Science. 247 (4943): 622. Bibcode:1990Sci...247..622P. doi:10.1126/science.2300819. PMID   2300819.
    Ullman, André; Teutsch, Georges; Philibert, Daniel (June 1990). "RU 486". Sci Am. 262 (6): 42–8. Bibcode:1990SciAm.262f..42U. doi:10.1038/scientificamerican0690-42. PMID   2343294.
    Teutsch, G.; Deraedt, R.; Philibert, D. (1993). "Mifepristone". In Lednicer, Daniel (ed.). Chronicles of drug discovery, Vol. 3. Washington, DC: American Chemical Society. pp.  1–43. ISBN   0-8412-2523-0.
    Philibert, Daniel; Teutsch, Georges (June 1994). "History and perspectives of antiprogestins from the chemist's point of view". Human Reproduction. 9 (Suppl 1): 12–31. doi:10.1093/humrep/9.suppl_1.12. PMID   7962457.
    Sittig, Marshall, ed. (2007). "Mifepristone". Pharmaceutical manufacturing encyclopedia (3rd ed.). Norwich, NY: William Andrew Publishing. pp. 2307–2310. ISBN   978-1-60119-339-1.
    USpatent 4,386,085,Teutsch, Jean G.; Costerousse, Germain; Philibert, Daniel; Deraedt, Roger,"Novel steroids",issued 1983-05-31 assigned to Roussel Uclaf
  9. ↑ Eder, Richard (April 20, 1982). "Birth control: 4-day pill is promising in early test" . The New York Times. p. C1.
    Herrmann, Walter; Wyss, Rolf; Riondel, Anne; Philibert, Daniel; Teutsch, Georges; Sakiz, Edouard; Baulieu, Étienne-Émile (May 17, 1982). "The effects of an antiprogesterone steroid in women: interruption of the menstrual cycle and of early pregnancy". Comptes Rendus de l'Académie des Sciences, Série III. 294 (18): 933–8. PMID   6814714.
  10. ↑ Kolata, Gina (September 24, 1988). "France and China allow sale of a drug for early abortion" . The New York Times. p. A1.
  11. ↑ Greenhouse, Steven (October 27, 1988). "Drug maker stops all distribution of abortion pill" . The New York Times. p. A1.
  12. ↑ Greenhouse, Steven (October 29, 1988). "France ordering company to sell its abortion drug" . The New York Times. p. A1.
  13. ↑ Smith, W. (September 1991). "Great Britain second country to allow use of RU-486". Plan Parent Eur. 20 (2): 20. PMID   12284548.
  14. ↑ "RU 486 licensed in Sweden". IPPF Med Bull. 26 (6): 6. December 1992. PMID   12346922.
  15. ↑ Newman, Barry (February 22, 1993). "Drug dilemma: among those wary of abortion pill is maker's parent firm; Germany's Hoechst is facing pressure from Clinton to sell RU-486 in U.S.". The Wall Street Journal. p. A1.
    "F.D.A. says company delays abortion pill" . The New York Times. Associated Press. April 16, 1993. p. A14.
    Jouzaitis, Carol (October 17, 1994). "Abortion pill battle surprises French firm". Chicago Tribune. p. 1 (Business).
  16. ↑ Seelye, Katharine Q. (May 17, 1994). "Accord opens way for abortion pill in U.S. in 2 years" . The New York Times. p. A1.
  17. ↑ Kolata, Gina (September 29, 2000). "U.S. approves abortion pill; drug offers more privacy and could reshape debate" . The New York Times. p. A1.
  18. ↑ Moore, Stephen D.; Kamm, Thomas; Fleming, Charles (December 11, 1996). "Hoechst to seek rest of Roussel-Uclaf; expected $3.04 billion offer would add to the wave of drug-sector linkups". The Wall Street Journal. p. A3.
    Marshall, Matt (December 11, 1996). "Hoechst offers to pay $3.6 billion for rest of Roussel". The Wall Street Journal. p. A8.
    "Hoechst to buy rest of Roussel" . The New York Times. Bloomberg Business News. December 11, 1996. p. D4.
  19. ↑ Bloomberg News (April 9, 1997). "Pill for abortion ends production" . The New York Times. p. D2.
    Jouzaitis, Carol (April 9, 1997). "Abortion pill maker bows to boycott heat; German firm gives up RU-486 patent; little impact likely in U.S." Chicago Tribune. p. 4.
    Lavin, Douglas (April 9, 1997). "Hoechst will stop making abortion pill". The Wall Street Journal. p. A3.
    "Roussel-Uclaf to transfer RU 486 rights". Reprod Freedom News. 6 (7): 8. April 18, 1997. PMID   12292550.
    Dorozynski, Alexander (April 19, 1997). "Boycott threat forces French company to abandon RU486". BMJ. 314 (7088): 1150. doi:10.1136/bmj.314.7088.1145m. PMC   2126515 . PMID   9146386.
  20. ↑ "List of mifepristone approval" (PDF). New York: Gynuity Health Projects. November 4, 2009.
    "Map of mifepristone approval" (PDF). New York: Gynuity Health Projects. November 4, 2009.

Sources

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.